Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 17/20 | 0.62 |
| ▸ | CPT1B | Q92523 | 7/20 | 0.52 |
| ▸ | CPT2 | P23786 | 10/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310181 | 1.00 | CPT1A (0.62) | CPT1ACPT1BCPT2HSD11B1USP30 | |
| SCHEMBL2356918 | 0.90 | CPT1A (0.64) | CPT1ACPT1BCPT2USP30 | |
| SCHEMBL2356915 | 0.90 | CPT1A (0.64) | CPT1ACPT1BCPT2USP30 | |
| SCHEMBL2307127 | 0.89 | CPT1A (0.66) | CPT1ACPT1BCPT2GPR119 | |
| SCHEMBL2307131 | 0.89 | CPT1A (0.66) | CPT1ACPT1BCPT2GPR119 | |
| SCHEMBL2310116 | 0.88 | CPT1A (0.54) | CPT1ACPT1BCPT2USP30GPR119 | |
| SCHEMBL2310113 | 0.88 | CPT1A (0.54) | CPT1ACPT1BCPT2USP30GPR119 | |
| SCHEMBL2308109 | 0.87 | CPT1A (0.67) | CPT1ACPT1BCPT2USP30 | |
| SCHEMBL2308104 | 0.87 | CPT1A (0.67) | CPT1ACPT1BCPT2USP30 | |
| SCHEMBL2311573 | 0.86 | CPT1A (0.67) | CPT1ACPT1BCPT2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2155738-B1 | PIPERIDINE-AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2155738-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT1B 2/4885CPT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.